IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)

NCT ID: NCT02232425

Last Updated: 2020-08-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 88 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2015-10-31

Brief Summary

The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong premature ejaculation.

Conditions

Premature Ejaculation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Drug: IX-01

Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity

Group Type: EXPERIMENTAL

IX-01

Intervention Type: DRUG

Placebo

Two to four capsules administered orally, 1-6 hours prior to sexual activity

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

IX-01

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• In stable (≥ 6 months) heterosexual relationship
• Have life-long (primary) premature ejaculation
• Have premature ejaculation confirmed by Intravaginal Ejaculatory Latency Time (IELT) less than or equal to (≤) 1 minute on ≥ 75% attempts at sexual intercourse
• Meet other aspects of the International Society for Sexual Medicine (ISSM) definition for lifelong premature ejaculation (PE), including inability to delay ejaculation on all or nearly all vaginal penetrations and negative personal consequences such as distress, bother and frustration
• Willing to attempt intercourse at least 4 times during run-in period and at least 8 more times during double-blind part of the study
• Not planning pregnancy with his partner and he is willing to use contraception (unless not of child-bearing potential, e.g., surgically sterilised)
• Willing to limit use of alcohol on days in which they take study drug (not more than three drinks, where one drink is defined as a 12 ounce (oz), 360 milliliter (mL) bottle of beer, a 5 oz (150 mL) glass of wine, or a 1½ oz (45 mL distilled spirits)
• Capable of giving written informed consent

Exclusion Criteria

• An Intravaginal Ejaculatory Latency Time (IELT) value ≥ 2 minutes during run-in period
• Less than (<) 4 attempts at sexual intercourse during run-in (screening may be extended or patient may be rescreened if there are extenuating circumstances)
• A rating of control of ejaculation as fair, good, or very good on the Premature Ejaculation Profile (PEP) questionnaire prior to study
• Co-existing Erectile Dysfunction - International Index of Erectile Dysfunction (IIEF) erectile function domain < 22 during run-in
• Concomitant use of Phosphodiesterase 5 (PDE5) inhibitors, intracavernosal injections, penile implants, Selective Serotonin Reuptake Inhibitors (SSRI's) or Serotonin-Norepinephrine Reuptake Inhibitors (SSNRI's), tricyclic antidepressants (for example (e.g.) clomipramine), monoamine oxidase inhibitors, alpha blockers, 5 alpha reductase inhibitors (including propecia for hair loss), topical anaesthetics, and/or tramadol
• History (last 6 months) of use of Botox or similar product to treat premature ejaculation
• Unwilling to stop other treatments for premature ejaculation (including but not limited to pharmacological, herbal, multiple condoms, psychosexual treatment, prior masturbation)
• Other sexual disorder of patient or partner that could interfere with results
• Current active sexually transmitted disease
• Major medical condition of patient that could interfere with ability to have sexual activity and or require hospital treatment
• Body Mass Index (BMI) > 40 kg/m2
• Participation in a clinical drug trial anytime during the 30 days prior to screening
• Human Immunodeficiency Virus (HIV) or hepatitis B
• History of clinically significant prostate disease
• History of myocardial infarction, coronary bypass surgery, coronary artery angioplasty, unstable angina, clinically evident congestive heart failure, cardiac pacemaker, or cerebrovascular accident
• Cardiac arrhythmia: significant cardiac arrhythmia shown on Electrocardiogram (ECG), or a known or suspected history of significant cardiac arrhythmias within last six months
• History of congenital QT prolongation and/ corrected QT (QTc) interval > 450 milliseconds (msec) using the Bazett formula
• Mean systolic cuff blood pressure (BP) > 140 millimeter of mercury (mmHg), as assessed by up to three measurements taken in sequence within 5-10 minutes of last measure
• Mean diastolic cuff BP > 90 mmHg, as assessed by up to three measurements taken in sequence within 5-10 minutes of the last measure
• Major psychiatric disease or risk of suicidal tendency as assessed by clinical evaluation and Patient Health Questionnaire (PHQ)-9 and Columbia Suicide Assessment
• PHQ-9 questionnaire total score > 9 and/or score > 0 for question 9 of PHQ-9, and/or suicidal ideation or behavior as assessed by Columbia Suicide Assessment
• Clinically significant abnormal laboratory function test results (including liver enzymes > 2 x Upper Limit of Normal (ULN) or bilirubin > 1.5 x ULN)
• Taking Cytochrome P450 3A4 (CYP3A4) inducers, or moderate and potent CYP3A4 inhibitors

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Carelon Research

OTHER

Sponsor Role: collaborator

Novotech (Australia) Pty Limited

INDUSTRY

Sponsor Role: collaborator

ICON plc

INDUSTRY

Sponsor Role: collaborator

PHT Corporation

INDUSTRY

Sponsor Role: collaborator

Ixchelsis Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Email Katie.George@Ixchelsis.com

Role: STUDY_DIRECTOR

Ixchelsis Limited

Locations

San Diego Sexual Medicine

San Diego, California, United States

South Florida Medical Research Inc.

Aventura, Florida, United States

Center for Marital and Sexual Health of South Florida

West Palm Beach, Florida, United States

Tulane University School of Medicine

New Orleans, Louisiana, United States

Cooper Research Institute

Camden, New Jersey, United States

Manhattan Medical Research

New York, New York, United States

Urologic Consultants of Southeastern Pennsylvania

Bala-Cynwyd, Pennsylvania, United States

Miriam Hospital / The Men's Health Center

Providence, Rhode Island, United States

Australian Centre for Sexual Health

Saint Leonards, New South Wales, Australia

Keogh Institute for Medical Research

Nedlands, Western Australia, Australia

Countries

United States; Australia

References

McMahon C, Althof S, Rosen R, Giuliano F, Miner M, Osterloh IH, Muirhead GJ, Harty B; PEPIX Multi-Centre Study Group. The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX). J Sex Med. 2019 Aug;16(8):1178-1187. doi: 10.1016/j.jsxm.2019.05.016.

Reference Type: DERIVED

PMID: 31351659 (View on PubMed)

Other Identifiers

IX-0103

Identifier Type: -

Identifier Source: org_study_id